|
23 Jul 2019 |
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
|
|
21 Jul 2019 |
PMZ-1620, an Endothelin-B Agonist, enters Phase III Trial in Patients with Cerebral Ischemic Stroke
|
|
21 Jul 2019 |
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
|
|
18 Jul 2019 |
MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
|
|
18 Jul 2019 |
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer
|
|
18 Jul 2019 |
Zydus announces completion of enrollment in three Phase III trials of Saroglitazar Magnesium in NASH
|
|
18 Jul 2019 |
Eisai presents nonclinical research results of elenbecestat of without significant effects on synaptic function in brain by spinal densitiy evaluation at effective dose to decrease amyloid beta level in cerebrospinal fluid at AAIC 2019
|
|
17 Jul 2019 |
Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
|
|
17 Jul 2019 |
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available
|
|
17 Jul 2019 |
Tradipitant Effective in Preventing Motion Sickness
|
|
17 Jul 2019 |
Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)
|
|
16 Jul 2019 |
Athira Pharma Presents Preliminary Results from Phase 1 Trial of NDX-1017 at Alzheimer's Association International Conference 2019 (AAIC)
|
|
16 Jul 2019 |
Axial Biotherapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder
|
|
16 Jul 2019 |
Cancer Targeted Technology Commences Phase I Clinical Trial in Prostate Cancer Patients with an Innovative Radiotherapy, CTT1403, and Receives a $3.2M NIH Grant to Fund the Trial
|
|
16 Jul 2019 |
Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
|
|
16 Jul 2019 |
Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors
|
|
15 Jul 2019 |
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
|
|
15 Jul 2019 |
Update on US regulatory decision for Farxiga in type-1 diabetes
|
|
13 Jul 2019 |
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
|
|
12 Jul 2019 |
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
|
|
12 Jul 2019 |
Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention
|
|
12 Jul 2019 |
Sensorion Receives FDA IND Approval for Arazasetron (SENS-401)
|
|
11 Jul 2019 |
Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
|
|
10 Jul 2019 |
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
|
|
10 Jul 2019 |
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
|
